拓扑替康联合顺铂治疗晚期非小细胞肺癌的近期疗效观察.docVIP

拓扑替康联合顺铂治疗晚期非小细胞肺癌的近期疗效观察 　　作者：焦克岗，戴月梅，孙峰 作者单位：新疆医科大学第一附属医院呼吸科，新疆乌鲁木齐830054 　　【摘要】 目的：分析拓扑替康联合顺铂治疗晚期非小细胞肺癌的疗效及毒副反应。方法：36例晚期非小细胞肺癌患者每天给予拓扑替康2 mg静滴，连续4~6 d，第1天加用顺铂70 mg/m2，21 d为一周期，评价患者症状改善情况和1、2年生存率及药物毒副反应。结果: 36例患者完全缓解 1例，部分缓解13例，总有效率达38.9%。除2例尚存活外，34例已死亡，存活3~28个月，平均16~21个月，1、2年生存率分别为47.2%、13.9%。毒副反应的发生率为69.4%，其中胃肠道反应占44.4%，白细胞下降占41.7%。结论: 拓扑替康联合顺铂治疗晚期非小细胞肺癌具有较好的疗效，毒副反应可以耐受。 　　【关键词】 拓扑替康;顺铂;化疗;非小细胞肺癌 　　An observation on shortterm effect of the combination of topotecan and cisplatin in the treatment of advanced nonsmall cell lung cancer 　　JIAO Kegang，DAI Yuemai，SUN feng 　　(Department of Respiration ，First Affiliated Hospital，Xinjiang Medical University， 　　Urumqi 830054， China) 　　Abstract：Objective：To analyze the efficacy and toxicity of the combination of topotecan and cisplatin in the treatment of patients with advanced nonsmall cell lung cancer (NSCLC). Methods: Thirtysix patients with advanced nonsmall cell lung cancer were enrolled into the study, the patients received topotecan (intravenous) 2 mg daily for 4~6 days and cisplatin 70 mg/m2 on day 1, 21day for each cycle. At last we evaluated the improvement of symptoms, the 1 or 2year survival rate and the adverse effects of drugs. Results: The overall response rate in the group was 38.9%, 1 patient had complete response (CR), 13 patients had partial response (PR). 2 patients were survival, 34 patients were dead, they had lived 3~28 months, the median survival time of 16~21 months. The 1 or 2year survival rates were 47.2% and 13.9%, respectively. The occurrence rate of toxicities were 69.4%; the disorders in gastrointestinal aspects account for 44.4%, leukopenia account for 41.7%. Conclusion: The combination of topotecan and cisplatin is effective and welltolerated in the treatment of advanced NSCLC. 　　Key words: topotecan; cisplatin; chemotherapy; nonsmall cell lung cancer 　　近年来肺癌发病率有逐年递增的趋势，每年全世界新增肺癌患者有100多万，且大多数患者为不宜手术的晚期非小细胞肺癌患者[1]。临床研究表明以顺铂为基础的联合化疗方案对大多数肺癌患者有较好